Filing Overview
Registrant: NLS Pharmaceutics Ltd. The request metadata identifies Newcelx Ltd., but the filing itself names NLS Pharmaceutics Ltd. as the registrant.
Form: Form 6-K for the month of January 2024; filed January 12, 2024. The registrant reports under Form 20-F and is based in Zurich, Switzerland.
Business and Financial Information
The filing reports the furnishing of a press release concerning Nasdaq continued-listing requirements. It does not provide revenue, profit, cash flow, margins, debt, liquidity, operating results, or other financial metrics.
Material Developments
- On January 12, 2024, NLS Pharmaceutics announced that it had received a notice of deficiency regarding Nasdaq continued-listing requirements.
- The filing does not state the specific listing deficiency, the applicable Nasdaq deadline, or the remediation steps in the provided text.
- The press release was furnished as Exhibit 99.1, but its substantive contents are not included in the provided filing text.
Outlook, Risks, and Unusual Items
The Nasdaq notice represents a potential continued-listing risk. The filing text does not provide management guidance, an outlook, contingency plans, or an assessment of the likelihood of regaining compliance.
Key Facts to Verify
- The specific Nasdaq continued-listing requirement allegedly not met.
- The deadline and process for regaining compliance, including any hearing or appeal rights.
- Whether the deficiency could result in suspension or delisting of the company’s securities.
- Any financial or operational consequences disclosed in the underlying Exhibit 99.1 press release.